Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where do you get hope for partnership on the near horizon? They have not started the trials that they hope will interest a partner. Does that seem near-term?
More likely institution. It"s a good day to get out if you needed to move alot of shares. I would hope pphm did not sell atm shares nto this austerity pr
$30k revenue per employee would be closer to ideal than the current headcount which is under $200k
Good day to sell.Sell into strength, buy into weakness.
non events
CA will be dismissed and PRed
European patent never been PRed
Official lauch of Avid will be PRed soon
AZN buying of IP between 250M and 500M and 10% royalties, US and ex-US
Avid expansion. Spin off or name change from PPHM to AVID... Dull but SAFE business.
3$ sooner than later especialy with the payroll reduction.
Expect surprises : 50-55 Milion will be 70 and in the black in 12 months instead of 24...
Short interest was not that high who knows but i am out .... till a selloff. Hope no one was "not trading , but short and adding to his long position".
I'll go on limb. Closing price $.42xx
Yes ...again no quote from him or comment about trials. Sure seems like he is gone.
Sell the news day (early) if there ever was one.
MC will be 4 to 5 times Avid sales.
Is it clear yet?
No secret BLA
No PII or PIII trials.
No partner in the wings
They hope future unstarted trials will drive partnership interest
the goal of these trials will be to generate compelling data capable of driving partnering interest
lots of cancelled trials there..... yet bavi works great with chemo, pii was statsig, just a strong control anomaly in Sunrise - right.
Only way avid could go public at this stage is reverse merger with shelf corp.
The comp at pphm is truly obscene given the performance. Where is the corporate governance at pphm? Oh yes, that would be the bod who are paid more than most Fortune 500 bod members. They really do leave themselves open to lawsuits with this contemptuous attitude towards shareholders.
1) Trial stopped for futility
2) Company stopped all bavi/chemo trials
Not sure how much more proof you need. a vague statement about performing as expected when you do not know what is meant by expected is not very valuable - hence the $.41. Not FUD , reality.
The last RS was NOT after the botched trial.
Can someone point me to where the company said they are going to do a RS! Until that happens the FUD speculations are just as ludicrous as the positive spins.
Looking for the bavi mention - nope Why do you suppose few will associate with pphm in all these ps related articles?
So pphm is at $.41 not $5.41 because of shorts? And here I thought the retracted PII data and failed PIII trial had something to do with share price. This is also just a continuation of in place shorting rules.
collaborations with AstraZeneca, NCCN (26 top cancer hospital networks..) and Memorial Sloan Kettering
30% you say?
http://www.nasdaq.com/symbol/pphm/institutional-holdings
I know Dart is not in there but your facts are wrong again. And after Russell ejection who knows.
I took this to mean they they would work with the same sites (who already were trained in the protocols). I believe they simply, when SUNRISE fully enrolled, told the sites to give the new patients the new drug instead of doce.....so they could be up and running quickly and easily (as in January).
and yet tiny mention of pphm. They really need some PR help.
Yes Russell market cap minimums can not be met by RS
And where is Garnick. Does he still consult to pphm. How can he go this long with no Sunrise statement, no upcoming trials info .....nothing. I think he is gone. Of course they can cut his hours back to 1 per month and still say he is on-board. Problem with non-employee regulatory head.
A doubling of median overall survival (OS) in both bavituximab-containing arms compared to the control arm and a statistically significant improvement in overall survival
no detail by design ? It is what you should realize is called strategic advancement with some enemies having no idea where you hide and some enemy of the enemy allying up with Peregrine Pharmaceuticals
Bavi not outperforming doce? not a fact
Paradigm shift is away from chemo Carboat.
Who knows what Bavi performed as expected means? It is a typical cya press release statement that has no detail by design.And bavi did not outperform doce, that is why the trial failed and was stopped for futility. If bavi was doing great why cancel the other trials. If bavi was doing great why no word from Garnick or anyone else about the future of bavi.
I do agree the game is over, how much more proof do you need then the shareprice $.41, the certain Russell eviction, the almost certain RS
This is the biggest paradigm shift re: Big Pharma
I doubt they would not do a RS of pphmp RS being such a negative event, low point, why subject the preferred holders. They will just adjust the conversion.
Here's a puzzle piece, why no mention of bavi in these PS related articles?
That is a unique interpretation for sure. So pphm issues a release that craters the stock from $5+ to < $1. It says, to quote you,
PPHM said that INVESTORS should not rely on the numbers to INVEST.
Painted the tape higher today in pphm-land - though I guess we should wait for TD to be sure the closing price is correct.
The boiler-room guys are having fun. A few hundred grand and you can move this anywhere you want. And people are think AZN, Calico etc. can you imagine going to investment committee and pitching a pphm investment or acquisition. Talk about a career-ender.
You must be using the same dictionary that gave you "sketchy" when you say "retracted."
So you can view the data as sketchy or retracted and I will view it as real statistically significant proo
He bought pphmp not pphm. he wanted the dividend. A case can clearly be made that he did not see any rapid share price appreciation in the short term based on buying preferred over common. So few shares through a non-event surely. Kinda like a low low volume share increase.
Recent data from the trial showed a doubling of median overall survival (OS) in both bavituximab-containing arms compared to the control arm and a statistically significant improvement in overall survival.
I say again: we saw an actual 130% improvement that bavi did over SOC
I figure that the 29.29% Institutional Investors is including Dart?
As opposed to your definitive statements as you see fit.
I hope I helped you unravel the mystery of your confusion.